GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare
GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare
Genetic Technologies (GENE) announces the development of a groundbreaking risk assessment test for serious diseases, incorporating over 200 high penetrant genes to identify nearly 100% of people at risk. The test covers common cancers, cardiovascular disease, and type 2 diabetes, going beyond family history to identify patients at risk of disease. This innovation aims to revolutionize personalized preventative healthcare, providing physicians and patients with unparalleled insight into individual risk profiles.
Positive
Development of a cutting-edge risk assessment test for serious diseases by Genetic TechnologiesIncorporates over 200 high penetrant genes to identify nearly 100% of people at risk of disease.Test covers common cancers, cardiovascular disease, and type 2 diabetes, going beyond family history.Aims to revolutionize personalized preventative healthcare by providing unparalleled insight into individual risk profiles.Saliva test remains at the core of GeneType's approach, ensuring accessibility and accuracy.Massive opportunity in the United States healthcare market for comprehensive genetic risk assessments.
Negative:None.
GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare | GENE Stock News (stocktitan.net)
